Suramin-induced neutropenia

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1534-1539

  Dawson, N A ^a,b   Lush, R M ^a   Steinberg, S M ^a   Tompkins, A C ^a   Headlee, D J ^a   Figg, W D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Granulocyte colony stimulating factor; Neutropenia; Prostatic neoplasms; Suramin; Toxicity

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FLUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUPRORELIN; PLATELET DERIVED GROWTH FACTOR; SURAMIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030218827     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00139-6     Document Type: Article

References (12)

1. 1. Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory prostate cancer. J Clin Oncol 1992, 10, 881-889.
2. 2. La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990, 2, 106-115.
3. 3. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993, 53, 2239-2248.
4. 4. Middaugh CR, Mach H, Burke CJ, et al. Nature of the interaction of growth factors with suramin. Biochemistry 1992, 31, 9016-9024.
5. 5. Dawson NA, Cooper MR, Figg WD, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995, 76, 453-462.
6. 6. Cooper MR, Lieberman R, La Rocca RV, et al. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther 1992, 52, 11-23.
7. 7. Wittes RE, ed. Manual of Oncologic Therapeutics: Appendix A. Grading of Toxicity. Philadelphia, JB Lipincott Co, 1989, 627-632.
8. 8. Supko JG, Malspeis L. A rapid isocratic HPLC assay of suramin in human plasma. J Liq Chromatogr 1993, 13, 727-741.
9. 9. Hoagland HC. Hematologic complications of cancer chemotherapy. In Perry MC, Yarboro JW, eds. Toxicity of Chemotherapy. New York, Grune & Stratton, Inc, 1984, 433-448.
10. 10. Foon KA. The cytokine network. Oncology 1993, 7, 11-15.
11. 11. Doukas M, Chavan A, Gass C, et al. Inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) activity by suramin and suramin analogues is correlated to interaction with the GM-CSF nucleotide-binding site. Cancer Res 1995, 55, 5161-5163.
12. 12. Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986, 22, 22-26.